Eton Pharmaceuticals(ETON) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results ● Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million or $0.02 per diluted share ● Entered into an asset purchase agreement to acquire Increlex® (mecasermin injection) ● Q3 2024 product sales increased 40% over Q3 2023, representing 15th straight quarter of sequential product sales growth ● Produced positive quarterly GAAP net income from product sales for first time in company history ● Generated cash fro ...